EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C13H17ClNO.Cl |
| Net Charge | 0 |
| Average Mass | 274.191 |
| Monoisotopic Mass | 273.06872 |
| SMILES | C[NH2+][C@]1(c2ccccc2Cl)CCCCC1=O.[Cl-] |
| InChI | InChI=1S/C13H16ClNO.ClH/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14;/h2-3,6-7,15H,4-5,8-9H2,1H3;1H/t13-;/m0./s1 |
| InChIKey | VCMGMSHEPQENPE-ZOWNYOTGSA-N |
| Roles Classification |
|---|
| Biological Roles: | analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. NMDA receptor antagonist Any substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. NMDA receptor antagonist Any substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs. |
| Applications: | analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| esketamine hydrochloride (CHEBI:60800) has part esketamine (CHEBI:60799) |
| esketamine hydrochloride (CHEBI:60800) has role analgesic (CHEBI:35480) |
| esketamine hydrochloride (CHEBI:60800) has role intravenous anaesthetic (CHEBI:38877) |
| esketamine hydrochloride (CHEBI:60800) has role NMDA receptor antagonist (CHEBI:60643) |
| esketamine hydrochloride (CHEBI:60800) is a ketamine hydrochloride (CHEBI:650657) |
| IUPAC Names |
|---|
| (1S)-1-(2-chlorophenyl)-N-methyl-2-oxocyclohexanaminium chloride |
| (2S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride |
| Synonyms | Source |
|---|---|
| esketamine HCl | ChEBI |
| (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone HCl | ChEBI |
| (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride | ChEBI |
| (S)-ketamine HCl | ChEBI |
| (S)-(+)-ketamine hydrochloride | ChEBI |
| (S)-ketamine hydrochloride | ChEBI |
| Brand Name | Source |
|---|---|
| Ketanest S | ChEBI |
| Manual Xrefs | Databases |
|---|---|
| DB01221 | DrugBank |
| Registry Numbers | Sources |
|---|---|
| Reaxys:4279015 | Reaxys |